Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell ...
‘Incredibly Encouraging’ Drug Trial Shrinks Tumors in Head and Neck Cancer Patients Within Six Weeks
But with amivantamab, they have an “incredibly encouraging” new option that was shown in a trial conducted across 11 ...
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...
By analyzing the tumor environment of diffuse large B-cell lymphoma (DLBCL), researchers from The University of Texas MD ...
Has come back (relapsed) within a year of treatment or does not go away (refractory) after your first treatment Has relapsed or is refractory and you cannot receive a hematopoietic stem cell ...
Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback